Brilinta

Brilinta Overdosage

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Full Prescribing Info
Overdosage
Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-limiting in a single ascending dose study. Other clinically meaningful adverse reactions which may occur with overdose include dyspnoea and ventricular pauses (see Adverse Reactions).
In the event of an overdose, observe for these potential adverse reactions and ECG monitoring should be considered.
There is currently no known antidote to reverse the effects of ticagrelor, and ticagrelor is not dialysable (see Pharmacology: Pharmacokinetics under Actions). Treatment of overdose should follow local standard medical practice. The expected effect of excessive ticagrelor dosing is prolonged duration of bleeding risk associated with platelet inhibition. Platelet transfusion is unlikely to be of clinical benefit in patients with bleeding (see Precautions). If bleeding occurs, appropriate supportive measures should be taken.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in